<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01240850</url>
  </required_header>
  <id_info>
    <org_study_id>FARM79BKPY</org_study_id>
    <secondary_id>2008−007353−12</secondary_id>
    <nct_id>NCT01240850</nct_id>
  </id_info>
  <brief_title>Methotrexate as a Steroid-sparing Agent in Idiopathic Retroperitoneal Fibrosis: a Randomised, Multicenter Trial</brief_title>
  <acronym>FIPREDEX</acronym>
  <official_title>Medical Therapy in Idiopathic Retroperitoneal Fibrosis: a Multicenter, Randomized, Controlled Trial of Prednisone vs Low-dose Prednisone Plus Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Parma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Parma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic periaortitis is a clinico-pathological entity encompassing idiopathic retroperitoneal
      fibrosis and perianeurysmal retroperitoneal fibrosis. The treatment of this disease is
      generally based on the use of glucocorticoids, which are often effective. However, prolonged
      steroid treatments are usually needed to achieve a sustained remission; additionally,
      patients frequently develop disease relapses following treatment discontinuation, therefore
      they may be exposed to high cumulative doses of glucocorticoids.

      Preliminary data reported in the literature show that methotrexate may be effective in
      combination with prednisone for retroperitoneal fibrosis. In addition, methotrexate is often
      used as a steroid-sparing agent in different inflammatory diseases.

      The aim of this study is to evaluate whether a treatment with low-dose prednisone plus
      methotrexate is non-inferior to conventional dose-prednisone in achieving remission in
      retroperitoneal fibrosis patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2007</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission rate by the end of treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in size of the retroperitoneal mass on CT/MRI scans</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of post-treatment relapses</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related toxicity</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Idiopathic Retroperitoneal Fibrosis</condition>
  <condition>Perianeurysmal Retroperitoneal Fibrosis</condition>
  <condition>Chronic Periaortitis</condition>
  <arm_group>
    <arm_group_label>Prednisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Methotrexate+Prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate+Prednisone</intervention_name>
    <description>Methotrexate will be added at a dose of 0.3 mg/kg/week (maximum dose, 20 mg/week, orally) to a reduced-dose prednisone regimen</description>
    <arm_group_label>Methotrexate+Prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <arm_group_label>Prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  New diagnosis of idiopathic retroperitoneal fibrosis or chronic periaortitis; written
             informed consent

        Exclusion Criteria:

          -  Secondary forms of retroperitoneal fibrosis (e.g. drugs, surgery, neoplasms,
             infections)

          -  Previous medical therapy for retroperitoneal fibrosis

          -  Renal failure with creatinine &gt;2 mg/dl which proved not to be reversible after
             ureteral decompression

          -  Hypersensitivity to the study drugs

          -  Pregnancy

          -  Active infections or malignant neoplasms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Augusto Vaglio, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Parma Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlo Buzio, MD</last_name>
    <phone>+39 0521 702345</phone>
    <email>carlo.buzio@unipr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Augusto Vaglio, MD, PhD</last_name>
    <phone>+39 0521 702345</phone>
    <email>augusto.vaglio@virgilio.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nephrology Unit, University Hospital of Parma</name>
      <address>
        <city>Parma</city>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Augusto Vaglio, MD PhD</last_name>
      <phone>+39 0521 702345</phone>
      <email>augusto.vaglio@virgilio.it</email>
    </contact>
    <investigator>
      <last_name>Augusto Vaglio, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>van Bommel EF, Siemes C, Hak LE, van der Veer SJ, Hendriksz TR. Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis treated with prednisone. Am J Kidney Dis. 2007 May;49(5):615-25.</citation>
    <PMID>17472843</PMID>
  </reference>
  <reference>
    <citation>Vaglio A, Palmisano A, Corradi D, Salvarani C, Buzio C. Retroperitoneal fibrosis: evolving concepts. Rheum Dis Clin North Am. 2007 Nov;33(4):803-17, vi-vii. Review.</citation>
    <PMID>18037118</PMID>
  </reference>
  <reference>
    <citation>Vaglio A, Salvarani C, Buzio C. Retroperitoneal fibrosis. Lancet. 2006 Jan 21;367(9506):241-51. Review.</citation>
    <PMID>16427494</PMID>
  </reference>
  <reference>
    <citation>Warnatz K, Keskin AG, Uhl M, Scholz C, Katzenwadel A, Vaith P, Peter HH, Walker UA. Immunosuppressive treatment of chronic periaortitis: a retrospective study of 20 patients with chronic periaortitis and a review of the literature. Ann Rheum Dis. 2005 Jun;64(6):828-33. Review.</citation>
    <PMID>15897305</PMID>
  </reference>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2010</study_first_submitted>
  <study_first_submitted_qc>November 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2010</study_first_posted>
  <last_update_submitted>November 12, 2010</last_update_submitted>
  <last_update_submitted_qc>November 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof Carlo Buzio</name_title>
    <organization>University of Parma</organization>
  </responsible_party>
  <keyword>Retroperitoneal fibrosis</keyword>
  <keyword>Inflammatory aneurysms</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Prednisone</keyword>
  <keyword>Aorta</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Retroperitoneal Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

